Semaglutide vs Tirzepatide for Women
Both semaglutide and tirzepatide are effective for weight management, but they differ in receptor targets, safety data specific to women, and clinical trial evidence.
Comparison Table
| Property | Semaglutide | Tirzepatide |
|---|---|---|
| Receptors | GLP-1R only | GIP + GLP-1R |
| CAS | 910463-68-2 | 2023788-19-2 |
| Weight Loss | ~15–17% | ~20–22% |
| FDA Approval | Yes (Ozempic/Wegovy) | Yes (Mounjaro/Zepbound) |
| Female Trial Data | Extensive (STEP program) | Good (SURMOUNT program) |
| Reproductive Safety Data | More published data | Less published data |
| Side Effect Profile | Predictable GI (nausea) | Similar GI + injection site |
The Venus Protocol Approach
The Venus Protocol uses Retatrutide — a triple GLP-1/GIP/GCGR agonist that surpasses both semaglutide and tirzepatide by adding the glucagon receptor for direct fat oxidation. This comparison remains useful for researchers considering single or dual agonists as alternatives within their protocols. Semaglutide and tirzepatide are also available individually from QSC.
The Venus Protocol — 10 Compounds
All 10 compounds from QSC. ≥99% HPLC purity, Janoshik COA, free domestic shipping.
Shop the Venus Protocol at QSC →Venus Protocol
Buy Compounds
QSC Research Network
Shop Venus Protocol →
Clavicular Ascension Stack →
Midas Longevity Protocol →
QSC Peptide Hub →
COA Verification →
QSC Wellness →
GLP-1 Research →
HGH Research →
Retatrutide →
Longevity Peptides →
Weight Loss Peptides →
Performance Peptides →
Research Peptides →
Peptide Clinic →
EU →
UK →
Australia →
Canada →
Asia (SG/TH/VN) →
Shop All QSC →